Skip to content

Tempus AI

US · TEM #1138 by market cap Listed 2024
70.35 -1.63 -2.26%
Live - 5344 symbols - heartbeat 289s ago · 2026-10-08 07:30
Pre-market 68.60 -2.49%
After-hours 70.25 -0.14%
Overnight 69.29 -1.51%
Market cap
12.69B
P/B
28.53
EPS
-1.41
Reader sentiment Are you bullish or bearish on TEM?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 33.26 In line with history 52nd percentile
5-year average 58.16 · #40 of 41 in Health Information Services
P/E ratio -56.95 Cheap vs history 19th percentile
5-year average -30.62 · forward -54.94
P/S ratio 10.33 In line with history 39th percentile
5-year average 11.14 · forward 8.33 · #35 of 42 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Tempus AI (TEM) 12.69B -48.85 28.53 0.00%
Veeva Systems (VEEV) 45.74B 46.31 6.15 0.00%
BrightSpring Health Services (BTSG) 12.62B 38.67 6.16 0.00%
Hinge Health (HNGE) 7.90B 73.14 22.93 0.00%
HealthEquity (HQY) 7.60B 33.18 3.82 0.00%
Waystar Holding (WAY) 4.94B 36.81 1.24 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value74.68 Economic moatNone UncertaintyHigh

Trading 6.2% below Morningstar's fair value estimate.

Fair value

Tempus AI Inc receives a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 10% premium over our quantitative fair value estimate of $74.68 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio sits in the top 1% globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be expensive.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's enterprise value to free cash flow ratio of 476.4, for example, lies in the top 10% compared with peers globally. This suggests limited cash flow is available for reinvestment or return to shareholders, which further promotes our unfavorable price/fair value ratio.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:30:12 · For reference only, not investment advice and not tailored to your situation.